electroCoreECOR
About: electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
Employees: 62
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
8% more capital invested
Capital invested by funds: $6.61M [Q2] → $7.15M (+$545K) [Q3]
7.0% more ownership
Funds ownership: 16.49% [Q2] → 23.49% (+7.0%) [Q3]
0% more funds holding
Funds holding: 22 [Q2] → 22 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Swayampakula Ramakanth 31% 1-year accuracy 53 / 173 met price target | 48%upside $25 | Buy Maintained | 18 Dec 2024 |